REVIEW PAPER<Br>Treatment options for patients with rheumatoid arthritis after inadequate response to tumour necrosis factor inhibitors

Piotr Wiland

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2008
vol. 46

Send email

Copy url:

abstract:

REVIEW PAPER
Treatment options for patients with rheumatoid arthritis after inadequate response to tumour necrosis factor inhibitors

Piotr Wiland

Reumatologia 2008; 46, 3: 159–167

Online publish date: 2008/07/09

View full text Get citation

Tumour necrosis factor (TNF-α) inhibitors have improved the clinical outcome of many patients with rheumatoid arthritis (RA). However, some patients do not respond well or have contraindications to these agents. The appropriate treatment strategy in refractory RA would be possible by optimizing concomitant conventional disease modifying antirheumatic drugs, increasing the dose of TNF-α inhibitor or shortening the dosing frequency, switching to another TNF-α inhibitor or switching to other new biological agents available for use in patients with RA such as abatacept or rituximab.

keywords:

rheumatoid arthritis, inadequate response to tumor necrosis factor inhibitors, infliximab, etanercept, adalimumab, abatacept, rituximab

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

REVIEW PAPERTreatment options for patients with rheumatoid arthritis after inadequate response to tumour necrosis factor inhibitors

Piotr Wiland

rheumatoid arthritis, inadequate response to tumor necrosis factor inhibitors, infliximab, etanercept, adalimumab, abatacept, rituximab

REVIEW PAPER
Treatment options for patients with rheumatoid arthritis after inadequate response to tumour necrosis factor inhibitors